Source: International Congress 2019 – Pulmonary hypertension: clinical
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Martin Ontiyuelo (Barcelona, Spain), A. Rodó Pin (Barcelona, Spain), I. Blanco (Barcelona, Spain), A. Herranz Blasco (Barcelona, Spain), L. Molina Ferragut (Barcelona, Spain), L. Piccari (Barcelona, Spain), J. Barberà (Barcelona, Spain), D. Rodríguez Chiaradía (Barcelona, Spain). Evolution of patients with Pulmonary Arterial Hypertension (PAH) six months after an exercise training program. 4753

Member's Comments

No comment yet.

Related content which might interest you: Patient perspectives on exercise training in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Adherence to exercise training in Pulmonary Arterial Hypertension (PAH) and impact of concurrent health problems Source: International Congress 2017 – Best abstracts in pulmonary rehabilitation in patients with chronic lung diseases Year: 2017 Improvement of hypoxemia in patients affected by Pulmonary Arterial Hypertension (PAH) after a session of Controlled Breathing (CB) Source: International Congress 2019 – Novel interventions and models of pulmonary rehabilitation Year: 2019 Safety related to maximal cardiopulmonary exercise testing in patients with pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Effects of pulmonary rehabilitation (PR) in idiopathic pulmonary arterial hypertension (PAHI) Source: Annual Congress 2013 –The latest insights in pulmonary rehabilitation (part 2) Year: 2013 Exercise-induced pulmonary pressure changes in scleroderma patients – A follow-up study Source: International Congress 2014 – Pulmonary hypertension: right ventricular function, exercise and gas exchange Year: 2014 Effect of combined training versus aerobic training in patients with Pulmonary Hypertension. Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension Year: 2017 Atorvastatin in Pulmonary Arterial Hypertension (APATH) study Source: Eur Respir J 2012; 40: 67-74 Year: 2012 Open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH) Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Exercise training added to usual care in pulmonary hypertension: A systematic review Source: International Congress 2015 – Latest insights into the management of chronic respiratory diseases Year: 2015 Exercise capacity in patients with Pulmonary Arterial Hypertension: multicentric analysis of aerobic capacity and survival Source: Virtual Congress 2020 – Exercise and haemodynamics in pulmonary hypertension Year: 2020 An evaluation of outcomes for patients with pulmonary hypertension (PH) incorporated into a standard UK pulmonary rehabilitation (PR) programme Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Pulmonary Function and response to treatment in pulmonary arterial hypertension (PAH) Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Is 6-minute walk distance (6MWD) associated with long-term outcomes in pulmonary arterial hypertension (PAH)? Results from SERAPHIN Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Demand for exercise training in patients with pulmonary arterial hypertension in Scotland Source: Eur Respir J 2015; 46: 1513-1515 Year: 2015 Usefulness of NT-proBNP dosage during the follow-up of PAH: Comparison with 6MWD Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Effects of 12-week exercise training-related rehabilitation on exertional dyspnoea in patients with idiopathic pulmonary arterial hypertension Source: International Congress 2015 – Clinical exercise physiology in health and disease Year: 2015 Exercise pulmonary hemodynamics in systemic sclerosis patients – Implications for outcome Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 LATE-BREAKING ABSTRACT: Riociguat for the treatment of pulmonary arterial hypertension (PAH): 2-year results from the PATENT-2 long-term extension Source: International Congress 2014 – New technologies and biomarkers in lung disease Year: 2014 Hyperoxia enhances exercise performance in PAH and CTEPH: Randomized trial Source: International Congress 2016 – Clinic of pulmonary hypertension Year: 2016